FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024369575> ?p ?o ?g. }

• W2024369575 endingPage "e57" @default.
• W2024369575 startingPage "e56" @default.
• W2024369575 abstract "New-onset diabetes after transplantation (NODAT) remains a frequent and serious complication after kidney transplantation (1). We previously reported NODAT in our postkidney transplant population at a frequency of more than 50%, using the definition established by the 2003 International Guidelines (2). This high rate of posttransplant diabetes has serious negative consequences for future cardiovascular risk and survival after kidney transplant (3). Many factors contribute to NODAT, including age, genetic background, obesity, and the use of immunosuppressants (2, 4). Despite the elimination of chronic glucocorticoids and minimization of immunosuppressants, NODAT remains a difficult problem (4). An ideal agent should stimulate beta-cell function, improve insulin resistance, be easily administered, and well tolerated without hypoglycemia. Finally, as our data have shown, NODAT occurs within the first 3 months posttransplant, so any pharmacologic intervention must be given soon after transplantation (2). The incretin class of agents may be suitable as treatment, or even prevention, for NODAT. These agents include glucagon-like peptide-1 agonists and the dipeptidyl peptidase (DPP)-4 inhibitors. They stimulate beta-cell function, slow gastric emptying, and decrease insulin resistance (5). The glucagon-like peptide-1 agonists also suppress appetite but may cause nausea and cannot be used with a low glomerular filtration rate (GFR). This leaves the orally administered DPP-4 inhibitors as potential candidates because they can be used with low GFR, infrequently cause nausea, and have a low hypoglycemia potential (6). We designed a 3-month pilot study to demonstrate the feasibility of using the DPP-4 inhibitor, sitagliptin, in a population of renal transplant recipients who had been diagnosed with NODAT. The primary endpoints included the effect of sitagliptin on tacrolimus and sirolimus levels and changes to renal function. Secondary endpoints included side effects and change in HbA1c. Fifteen patients were recruited for a 3-month study through the University of Nebraska Medical Center (UNMC) Clinical Research Center. The study was approved by the UNMC Institutional Review Board. All patients met the definition of NODAT (1). Patients had an estimated GFR (eGFR) more than 30 ml/min according to the Modification of Diet in Renal Disease study, were free of other chronic illnesses, and had a HbA1c of 6.5% to 10.0%. Our immunosuppression regimen was free of glucocorticoids and used low-dose tacrolimus (target levels 2–4 ng/mL) and sirolimus (target levels 4–6 ng/mL) (7). Patients were treated with sitagliptin at a standard dose of 100 mg orally each day with dosing adjusted based on eGFR, per package insert. Tacrolimus and sirolimus levels and serum creatinine were obtained weekly, while HbA1c was measured at 0 and 12 weeks. Patients were aged 52.1±4.0 years (mean±SD), 11 of 15 were male, 12 of 15 were whites, and body mass index was 34.0±1.8 kg/m2. They had been diagnosed with NODAT 1.8±0.3 years and were 4.7±1.0 years posttransplant. Mean blood pressure on entry was 139±5/78±3 mm Hg. Figure 1 demonstrates that over the course of the study, there was no significant change in tacrolimus or sirolimus levels, using nonparametric repeated measures analysis of variance testing. Similarly, there was no change in eGFR over the course of the study. eGFR was 58.9±4.4 mL/min at entry and 60.5±5.6 mL/min at week 12. Neither tacrolimus nor sirolimus doses changed over the study. HbA1c improved from a baseline of 7.2%±0.1% to 6.7%±0.2% (P=0.002).FIGURE 1.: Mean drug levels for sirolimus, tacrolimus, and eGFR over time. eGFR, estimated glomerular filtration rate.No patient discontinued the use of sitagliptin because of side effects. No patients had symptomatic hypoglycemia, although some were on more than one agent for NODAT. Side effects included mild abdominal discomfort, loose stools, nausea, and headaches. It should be noted that the highest rates of NODAT occur in patients who receive calcineurin inhibitors for immunosuppression (1). In addition, sirolimus has also been associated with NODAT (4). It is interesting to note that despite exposure to tacrolimus and sirolimus, there was an improvement in HbA1c similar to that seen in other patients with type 2 diabetes (8). These results suggest that further studies should be pursued with DPP-4 inhibitors in patients with NODAT, as part of a comprehensive treatment plan. This might even extend to treatment of patients without NODAT during the first 6 months after transplant, when immunosuppressant exposure is the greatest. In conclusion, we have shown that sitagliptin, in a pilot study, is capable of inducing a clinically significant decrease in HbA1c in patients who have NODAT after kidney transplant, without altering tacrolimus or sirolimus drug levels or eGFR and with minimal side effects. James T. Lane1 David E. Odegaard1 Claire E. Haire1 Dean S. Collier2 Lucile E. Wrenshall3 R. Brian Stevens3 1 Department of Internal Medicine University of Nebraska Medical Center Omaha, NE 2 College of Pharmacy University of Nebraska Medical Center Omaha, NE 3 Department of Surgery University of Nebraska Medical Center Omaha, NE" @default.
• W2024369575 created "2016-06-24" @default.
• W2024369575 creator A5000229299 @default.
• W2024369575 creator A5026738153 @default.
• W2024369575 creator A5030005728 @default.
• W2024369575 creator A5037387824 @default.
• W2024369575 creator A5048020782 @default.
• W2024369575 creator A5086360508 @default.
• W2024369575 date "2011-11-27" @default.
• W2024369575 modified "2023-10-01" @default.
• W2024369575 title "Sitagliptin Therapy in Kidney Transplant Recipients With New-Onset Diabetes After Transplantation" @default.
• W2024369575 cites W2011215652 @default.
• W2024369575 cites W2027132230 @default.
• W2024369575 cites W2032322539 @default.
• W2024369575 cites W2058150151 @default.
• W2024369575 cites W2058866009 @default.
• W2024369575 cites W2085862152 @default.
• W2024369575 cites W2166436958 @default.
• W2024369575 cites W2792263124 @default.
• W2024369575 doi "https://doi.org/10.1097/tp.0b013e3182347ea4" @default.
• W2024369575 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22067216" @default.
• W2024369575 hasPublicationYear "2011" @default.
• W2024369575 type Work @default.
• W2024369575 sameAs 2024369575 @default.
• W2024369575 citedByCount "68" @default.
• W2024369575 countsByYear W20243695752012 @default.
• W2024369575 countsByYear W20243695752013 @default.
• W2024369575 countsByYear W20243695752014 @default.
• W2024369575 countsByYear W20243695752015 @default.
• W2024369575 countsByYear W20243695752016 @default.
• W2024369575 countsByYear W20243695752017 @default.
• W2024369575 countsByYear W20243695752018 @default.
• W2024369575 countsByYear W20243695752019 @default.
• W2024369575 countsByYear W20243695752020 @default.
• W2024369575 countsByYear W20243695752021 @default.
• W2024369575 countsByYear W20243695752022 @default.
• W2024369575 countsByYear W20243695752023 @default.
• W2024369575 crossrefType "journal-article" @default.
• W2024369575 hasAuthorship W2024369575A5000229299 @default.
• W2024369575 hasAuthorship W2024369575A5026738153 @default.
• W2024369575 hasAuthorship W2024369575A5030005728 @default.
• W2024369575 hasAuthorship W2024369575A5037387824 @default.
• W2024369575 hasAuthorship W2024369575A5048020782 @default.
• W2024369575 hasAuthorship W2024369575A5086360508 @default.
• W2024369575 hasBestOaLocation W20243695751 @default.
• W2024369575 hasConcept C126322002 @default.
• W2024369575 hasConcept C134018914 @default.
• W2024369575 hasConcept C159641895 @default.
• W2024369575 hasConcept C2777180221 @default.
• W2024369575 hasConcept C2777391703 @default.
• W2024369575 hasConcept C2778881409 @default.
• W2024369575 hasConcept C2779284873 @default.
• W2024369575 hasConcept C2780303639 @default.
• W2024369575 hasConcept C2780580376 @default.
• W2024369575 hasConcept C2780668416 @default.
• W2024369575 hasConcept C2908647359 @default.
• W2024369575 hasConcept C2911091166 @default.
• W2024369575 hasConcept C555293320 @default.
• W2024369575 hasConcept C71924100 @default.
• W2024369575 hasConcept C90924648 @default.
• W2024369575 hasConcept C99454951 @default.
• W2024369575 hasConceptScore W2024369575C126322002 @default.
• W2024369575 hasConceptScore W2024369575C134018914 @default.
• W2024369575 hasConceptScore W2024369575C159641895 @default.
• W2024369575 hasConceptScore W2024369575C2777180221 @default.
• W2024369575 hasConceptScore W2024369575C2777391703 @default.
• W2024369575 hasConceptScore W2024369575C2778881409 @default.
• W2024369575 hasConceptScore W2024369575C2779284873 @default.
• W2024369575 hasConceptScore W2024369575C2780303639 @default.
• W2024369575 hasConceptScore W2024369575C2780580376 @default.
• W2024369575 hasConceptScore W2024369575C2780668416 @default.
• W2024369575 hasConceptScore W2024369575C2908647359 @default.
• W2024369575 hasConceptScore W2024369575C2911091166 @default.
• W2024369575 hasConceptScore W2024369575C555293320 @default.
• W2024369575 hasConceptScore W2024369575C71924100 @default.
• W2024369575 hasConceptScore W2024369575C90924648 @default.
• W2024369575 hasConceptScore W2024369575C99454951 @default.
• W2024369575 hasIssue "10" @default.
• W2024369575 hasLocation W20243695751 @default.
• W2024369575 hasLocation W20243695752 @default.
• W2024369575 hasLocation W20243695753 @default.
• W2024369575 hasOpenAccess W2024369575 @default.
• W2024369575 hasPrimaryLocation W20243695751 @default.
• W2024369575 hasRelatedWork W1979252938 @default.
• W2024369575 hasRelatedWork W2049369825 @default.
• W2024369575 hasRelatedWork W2054192975 @default.
• W2024369575 hasRelatedWork W2071038866 @default.
• W2024369575 hasRelatedWork W2111110328 @default.
• W2024369575 hasRelatedWork W2144299763 @default.
• W2024369575 hasRelatedWork W2169206971 @default.
• W2024369575 hasRelatedWork W2378290744 @default.
• W2024369575 hasRelatedWork W2584731720 @default.
• W2024369575 hasRelatedWork W3003972117 @default.
• W2024369575 hasVolume "92" @default.
• W2024369575 isParatext "false" @default.
• W2024369575 isRetracted "false" @default.
• W2024369575 magId "2024369575" @default.
• W2024369575 workType "article" @default.